Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model-Reference-Cited by-同舟云学术

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

Published:2017-01-04 Issue:6 Volume:57 Page:796-804
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Freise Kevin J.¹,Shebley Mohamad¹,Salem Ahmed Hamed¹

Affiliation:

1. AbbVie, Inc; North Chicago IL, USA

Funder

AbbVie

Genentech

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference30 articles.

1. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets;Souers;Nat Med,2013

2. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia;Roberts;N Engl J Med,2016

3. A phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma;Davids;J Clin Oncol,2016

4. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results;Moreau;Blood,2015

5. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study;Stilgenbauer;Lancet Oncol,2016

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Inhibition of P-Glycoprotein Asymmetrically Alters the In Vivo Exposure Profile of SGC003F: A Novel Guanylate Cyclase Stimulator;Pharmaceuticals;2024-08-29

3. Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method;Anti-Cancer Drugs;2024-07-08

4. Plasma Venetoclax Concentrations in Patients with Acute Myeloid Leukemia Treated with CYP3A4 Inhibitors;YAKUGAKU ZASSHI;2024-07-01

5. Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review;Drug Design, Development and Therapy;2024-05